(Q38601420)

4 September 2017

Natural and therapy-induced immunosurveillance in breast cancer (English)

1 reference

4 September 2017

1 reference

2

Laura Senovilla

0 references

Laurence Zitvogel

5

Laurence Zitvogel

0 references

Guido Kroemer

1

Guido Kroemer

0 references

Lorenzo Galluzzi

3

Lorenzo Galluzzi

0 references

Fabrice André

4

Fabrice André

0 references

language of work or name

English

0 references

publication date

1 October 2015

1 reference

4 September 2017

1 reference

4 September 2017

21

1 reference

4 September 2017

10

1 reference

4 September 2017

1128-1138

1 reference

https://scigraph.springernature.com/pub.10.1038/nm.3944

4 September 2017

0 references

cites work

The Hallmarks of Cancer

1 reference

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

7 January 2021

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

7 January 2021

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

1 reference

7 January 2021

Cancer despite immunosurveillance: immunoselection and immunosubversion

1 reference

7 January 2021

Immune modulation in cancer with antibodies

1 reference

7 January 2021

Immune Checkpoint Blockade in Cancer Therapy

1 reference

7 January 2021

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

1 reference

7 January 2021

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

1 reference

7 January 2021

Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.

1 reference

7 January 2021

Molecular portraits of human breast tumours

1 reference

7 January 2021

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome

1 reference

7 January 2021

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

1 reference

7 January 2021

Stromal gene expression predicts clinical outcome in breast cancer

1 reference

7 January 2021

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

1 reference

7 January 2021

1 reference

7 January 2021

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

1 reference

7 January 2021

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

7 January 2021

Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies

1 reference

7 January 2021

Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration

1 reference

7 January 2021

Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy

1 reference

7 January 2021

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

1 reference

7 January 2021

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

1 reference

7 January 2021

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

1 reference

7 January 2021

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

1 reference

7 January 2021

The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

1 reference

7 January 2021

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

1 reference

7 January 2021

Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer.

1 reference

7 January 2021

Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer.

1 reference

7 January 2021

Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma.

1 reference

7 January 2021

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients

1 reference

7 January 2021

Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer

1 reference

7 January 2021

CD4⁺ follicular helper T cell infiltration predicts breast cancer survival

1 reference

7 January 2021

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

1 reference

7 January 2021

The immune contexture in human tumours: impact on clinical outcome

1 reference

7 January 2021

T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.

1 reference

7 January 2021

Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression

1 reference

7 January 2021

Clinical implication of HLA class I expression in breast cancer

1 reference

7 January 2021

The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer

1 reference

7 January 2021

Total loss of MHC class I is an independent indicator of good prognosis in breast cancer

1 reference

7 January 2021

Towards a systems understanding of MHC class I and MHC class II antigen presentation.

1 reference

7 January 2021

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

1 reference

7 January 2021

Impact of myeloid cells on the efficacy of anticancer chemotherapy

1 reference

7 January 2021

High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer

1 reference

7 January 2021

Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome

1 reference

7 January 2021

Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States

1 reference

7 January 2021

Cancer and the gut microbiota: an unexpected link

1 reference

7 January 2021

Influence of Antibiotic Treatment on Breast Carcinoma Development in Proto-neu Transgenic Mice

1 reference

7 January 2021

Antibiotic use in relation to the risk of breast cancer

1 reference

7 January 2021

Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation.

1 reference

7 January 2021

Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer.

1 reference

7 January 2021

Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy

1 reference

7 January 2021

Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression

1 reference

7 January 2021

Immunogenic cell death in cancer therapy

1 reference

7 January 2021

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

1 reference

7 January 2021

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

1 reference

7 January 2021

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy

1 reference

7 January 2021

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

7 January 2021

An immunosurveillance mechanism controls cancer cell ploidy

1 reference

7 January 2021

TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy

1 reference

7 January 2021

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors

1 reference

7 January 2021

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

7 January 2021

FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells.

1 reference

7 January 2021

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells

1 reference

7 January 2021

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy

1 reference

7 January 2021

Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours

1 reference

7 January 2021

High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer.

1 reference

7 January 2021

Leukocyte composition of human breast cancer

1 reference

7 January 2021

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

1 reference

7 January 2021

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

1 reference

7 January 2021

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

1 reference

7 January 2021

Programmed cell removal: a new obstacle in the road to developing cancer

1 reference

7 January 2021

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

1 reference

7 January 2021

Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients

1 reference

7 January 2021

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice

1 reference

7 January 2021

Autophagy in malignant transformation and cancer progression

1 reference

7 January 2021

The prognostic value of autophagy-related markers beclin-1 and microtubule-associated protein light chain 3B in cancers: a systematic review and meta-analysis

1 reference

7 January 2021

Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.

1 reference

7 January 2021

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

1 reference

7 January 2021

Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer

1 reference

7 January 2021

Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists

1 reference

7 January 2021

5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.

1 reference

7 January 2021

Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis.

1 reference

7 January 2021

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

1 reference

7 January 2021

A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice

1 reference

7 January 2021

Targeting HER2 for the treatment of breast cancer

1 reference

7 January 2021

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

7 January 2021

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

7 January 2021

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831

1 reference

7 January 2021

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.

1 reference

7 January 2021

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

1 reference

7 January 2021

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

1 reference

7 January 2021

Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene

1 reference

7 January 2021

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

1 reference

7 January 2021

Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients

1 reference

7 January 2021

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

1 reference

7 January 2021

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

1 reference

7 January 2021

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

1 reference

7 January 2021

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

1 reference

7 January 2021

Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice

1 reference

7 January 2021

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

1 reference

7 January 2021

The GP2 peptide: a HER2/neu-based breast cancer vaccine

1 reference

7 January 2021

Immunotherapy for the treatment of breast cancer

1 reference

7 January 2021

Therapeutic vaccines for cancer: an overview of clinical trials

1 reference

7 January 2021

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

1 reference

7 January 2021

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

1 reference

7 January 2021

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

1 reference

7 January 2021

HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells

1 reference

7 January 2021

Classification of current anticancer immunotherapies

1 reference

7 January 2021

Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis

1 reference

7 January 2021

Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer

1 reference

7 January 2021

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

1 reference

7 January 2021

Tumor-antigen-binding bispecific antibodies for cancer treatment

1 reference

7 January 2021

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

7 January 2021

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

7 January 2021

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

1 reference

7 January 2021

Prognostic and predictive value of PDL1 expression in breast cancer

1 reference

7 January 2021

PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients

1 reference

7 January 2021

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

1 reference

7 January 2021

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

1 reference

7 January 2021

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

7 January 2021

Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody

1 reference

7 January 2021

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs

1 reference

7 January 2021

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor

1 reference

7 January 2021

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

1 reference

7 January 2021

The Absence or Overexpression of IL-15 Drastically Alters Breast Cancer Metastasis via Effects on NK Cells, CD4 T Cells, and Macrophages

1 reference

7 January 2021

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

1 reference

7 January 2021

Identifiers

DOI

10.1038/NM.3944

1 reference

PubMed ID

26444637

Dimensions Publication ID

4 September 2017

0 references

1 reference

PubMed ID

26444637